ATNXQ — Athenex Share News
0.000.00%
Last trade - 00:00HealthcareHighly SpeculativeMicro Cap
- $0.13m
- $74.91m
- $102.82m
Brief: Athenex And Center For Cell And Gene Therapy Announce Allowance Of Our First U.S. Patent Claims Around CAR-NKT Cell Therapy
U.S. RESEARCH ROUNDUP-Adamas Pharmaceuticals, Carvana, Parker-Hannifin
Brief: Athenex Inc Provides Update From FDA Type A Meeting Regarding Oral Paclitaxel + Encequidar In Metastatic Breast Cancer
U.S. STOCKS ON THE MOVE-Beyond Meat, U.S. banks, U.S. insurers
U.S. STOCKS ON THE MOVE-ReWalk Robotics, Kraton, Blackstone
Athenex rises on launch of skin disease drug in Germany, UK
Brief: Athenex Announces Phased European Launch Of Klisyri For Treatment Of Actinic Keratosis
Brief: Athenex Presents Data From Oral Paclitaxel + Pembrolizumab Phase 1 Study At Esmo 2021
Brief: Athenex Inc - On August 20, Entered Into A Sales Agreement
U.S. RESEARCH ROUNDUP- Motorola Solutions, Papa John's International, Thomson Reuters
Athenex Inc reports results for the quarter ended in June - Earnings Summary
Brief: Athenex Says CFO Randoll Sze, Notified Co Of His Decision To Step Down
Athenex Inc expected to post a loss of 37 cents a share - Earnings Preview
Brief: Athenex Inc Files Mixed Shelf Of Upto $300 Million
Brief: Athenex Announces Additional Licensing Agreements For Tirbanibulin
Brief: Athenex Announces European Commission Approval Of Klisyri® (Tirbanibulin) For The Topical Treatment Of Actinic Keratosis
Athenex drops after FDA restates need for new trial for breast cancer treatment
Brief: Athenex Provides Update From FDA Type A Meeting Regarding Oral Paclitaxel Plus Encequidar For The Treatment Of Metastatic Breast Cancer
Brief: Athenex Presents Data On Oral Docetaxel And Oral Paclitaxel At Asco2021 Virtual Scientific Program